|1.||Geroni, C: 3 articles (03/2003 - 03/2001)|
|2.||Moneta, D: 3 articles (03/2003 - 03/2001)|
|3.||de Jonge, M J A: 2 articles (03/2003 - 12/2002)|
|4.||Brughera, M: 2 articles (03/2003 - 04/2001)|
|5.||Valota, O: 2 articles (03/2003 - 12/2002)|
|6.||Sessa, C: 2 articles (03/2003 - 12/2002)|
|7.||Fiorentini, F: 2 articles (12/2002 - 03/2001)|
|8.||Arrigoni, C: 2 articles (04/2001 - 03/2001)|
|9.||Della Torre, P: 2 articles (04/2001 - 03/2001)|
|10.||Ripamonti, M: 2 articles (03/2001 - 03/2001)|
03/01/2001 - "In addition, PNU-159548 was effective against intracranially implanted tumors. "
03/01/2001 - "These findings support the conclusion that PNU-159548 is an excellent candidate for clinical trials in the treatment of cancer."
03/01/2001 - "PNU-159548 showed good cytotoxic activity in murine and human cancer cells growing in vitro, with an average concentration for 50% growth inhibition of 15.8 ng/ml. The drug showed strong antitumor efficacy in vivo after i.v. and p.o. "
03/01/2001 - "The results obtained clearly indicate that the new anticancer agent PNU-159548 is able to overcome the classical mechanisms of resistance emerging after treatment with the most clinically used anticancer agents, and it could represent an alternate choice in the treatment of those tumors refractory to conventional therapy."
12/01/2002 - "In these studies, the DLT of PNU-159548 was thrombocytopenia. "
03/01/2003 - "Inhibition of common haemopoietic progenitors by PNU-159548 induced neutropenia/thrombocytopenia in animals and thrombocytopenia in patients, probably due to the higher sensitivity to the compound observed in human colony forming units-megakaryocyte (CFU-MK)."
|4.||Osteosarcoma (Osteogenic Sarcoma)
09/01/2005 - "4-Demethoxy-3'-deamino-3'-aziridinyl-4'-methylsulphonyl-daunorubicin (PNU-159548): a promising new candidate for chemotherapeutic treatment of osteosarcoma patients."
09/01/2005 - "Sequential exposure to PNU-159548 followed immediately by doxorubicin, methotrexate, or cisplatin was the most effective sequence of administration, invariably resulting in additive or synergistic effects in both drug-sensitive and drug-resistant osteosarcoma cell lines. "
09/01/2005 - "In conclusion, the high in vitro effectiveness, the absence of cross-resistance with doxorubicin, methotrexate, or cisplatin and the possibility to be successfully used in combination with these drugs indicate PNU-159548 as a promising candidate to be considered for planning new therapeutic regimens for osteosarcoma patients, who show a decreased response to conventional chemotherapy."
|1.||Drug Therapy (Chemotherapy)